Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $123,914.88 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 9,696 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $123,914.88. Following the sale, the general counsel now owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jonathan Allan also recently made the following trade(s):

• On Monday, December 9th, Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock. The stock was sold at an average price of $13.61, for a total value of $185,994.26.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $12.32 on Friday. Stoke Therapeutics, Inc. has a one year low of $4.09 and a one year high of $17.58. The business has a fifty day simple moving average of $12.48 and a 200 day simple moving average of $13.67.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on STOK shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday. Leerink Partners began coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $20.83.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Lynx1 Capital Management LP raised its stake in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter worth about $19,835,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Logos Global Management LP bought a new position in Stoke Therapeutics during the 2nd quarter valued at about $14,186,000. Finally, Marshall Wace LLP boosted its position in Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after buying an additional 982,451 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.